Sector
PharmaceuticalsCMP
as on 03 Jul, 2024 12:00:00 AM
Open
₹357.15Prev. Close
₹356.7Turnover(Lac.)
₹23,908.79Day's High
₹365.9Day's Low
₹356.5552 Week's High
₹361.952 Week's Low
₹217.5Book Value
₹91.91Face Value
₹5Mkt Cap (₹ Cr.)
43,395.69P/E
401.5EPS
0.9Divi. Yield
0.1411 Jun 2024
12:00 AM
Board Meeting
Agenda : Audited Result
23 May 2023
12:00 AM
Dividend
Dividend Amount: 1.5
Record Date: 07 Jul, 2023
23 May 2023
12:00 AM
AGM
Announcement Date: 23 May, 2023
| Y/e 31 Mar( In .Cr) | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|
Equity Capital | 600.3 | 600.3 | 600 | 600 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 10,315.7 | 7,492.6 | 7,307.1 | 6,937.3 |
Net Worth | 10,916 | 8,092.9 | 7,907.1 | 7,537.3 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Revenue | 1,738.2 | 2,028.4 | 1,988.4 | 2,419.2 |
yoy growth (%) | -14.3 | 2.01 | -17.8 | -6.51 |
Raw materials | -808.2 | -798.3 | -827.7 | -1,049.4 |
As % of sales | 46.49 | 39.35 | 41.62 | 43.37 |
Employee costs | -367.7 | -390.2 | -344.8 | -408.6 |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Profit before tax | 139.7 | 358.8 | 388.5 | 305.8 |
Depreciation | -108.2 | -103.5 | -98 | -136.1 |
Tax paid | -53.6 | -78.3 | -111.9 | -67.3 |
Working capital | 268.3 | 64.09 | 379.5 | -311.6 |
Other operating items |
| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | -14.3 | 2.01 | -17.8 | -6.51 |
Op profit growth | -80.44 | 9.26 | -10.11 | -46.23 |
EBIT growth | -60.99 | -7.82 | 27.02 | -43.18 |
Net profit growth | -69.3 | -36.38 | 84.86 | -54.07 |
| Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|---|
Gross Sales | 14,755.7 | 11,174.2 | 8,184 | 7,143.1 | 6,300.5 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 14,755.7 | 11,174.2 | 8,184 | 7,143.1 | 6,300.5 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 865.5 | 375.9 | 212.7 | 267.1 | 228.9 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,527.5 | 120.29 | 3,65,682.64 | 867.6 | 0.89 | 5,536.99 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 4,590 | 76.97 | 1,21,312.5 | 531 | 0.66 | 2,259 | 507.93 |
Cipla Ltd CIPLA | 1,485.45 | 32.36 | 1,20,195.02 | 1,038.4 | 0.57 | 3,444.92 | 346.41 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,110.3 | 31.35 | 1,08,114.81 | 1,405.2 | 0.28 | 3,172.6 | 156.19 |
Dr Reddys Laboratories Ltd DRREDDY | 6,440.35 | 24.48 | 1,06,298.05 | 1,034.8 | 0.63 | 5,081.8 | 1,453.02 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairperson
Kiran Mazumdar Shaw
Director
Ravi Mazumdar
Independent Director
Vijay Kumar Kuchroo
Independent Director
M Damodaran
Independent Director
Bobby Parikh
Company Sec. & Compli. Officer
Mayank Verma
Managing Director & CEO
SIDDHARTH MITTAL
Director
Eric Vivek Mazumdar
Independent Director
Naina Lal Kidwai
Independent Director
Peter John Bains
Additional Director
Atul Dhawan
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Biocon Ltd
Summary
Biocon Limited is Indias largest and fully-integrated, innovation-led biopharmaceutical company. The Company is engaged in the manufacture of biotechnology products and research services. Biocon Limited was incorporated in the year 1978 as a joint venture between Biocon Biochemicals Limited of Ireland and an Indian entrepreneur, Kiran Mazumdar-Shaw. Biocon manufactured and exported enzymes to USA and Europe during the year 1979, as first of its kind. In 1989, Unilever plc acquired the Biocon Biochemicals Limited in Ireland and merges it with its subsidiary, Quest International. Also in the same year, the company had received US funding for proprietary technologies. After a year, in 1990, Biocon had scaled up its in-house research programme, based on a proprietary solid substrate fermentation technology, from pilot to plant level. Biocons R&D and manufacturing facilities received ISO 9001 certification from RWTUV, Germany during the period of 1993. In the year 1994, the company had established the Syngene International Pvt. Ltd. as a Custom research Company (CRC) to address the growing need for outsourced R&D in the pharmaceutical sector. The commercial success of Biocons proprietary fermentation plant leads to a 3-fold expansion during the year 1996 and also in the same year, the company had leveraged its technology platform to enter biopharmaceuticals and statins. Biocon had spearheads initiatives in human healthcare in the year 1997 through a dedicated manufacturing facilit
Read More
What is the Biocon Ltd share price today?
The Biocon Ltd shares price on nse is Rs.₹361.45 today.
What is the Market Cap of Biocon Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Biocon Ltd is ₹43395.69 Cr. as of 03 Jul ‘24
What is the PE and PB ratio of Biocon Ltd?
The PE and PB ratios of Biocon Ltd is 401.5 and 3.98 as of 03 Jul ‘24
What is the 52 Week High and Low of Biocon Ltd?
The 52-week high/low is the highest and lowest price at which a Biocon Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Biocon Ltd is ₹217.5 and ₹361.9 as of 03 Jul ‘24
What is the CAGR of Biocon Ltd?
Biocon Ltd's CAGR for 5 Years at 7.00%, 3 Years at -4.38%, 1 Year at 35.37%, 6 Month at 34.00%, 3 Month at 32.09% and 1 Month at 15.19%.
What is the shareholding pattern of Biocon Ltd?
The shareholding pattern of Biocon Ltd is as follows:
Promoters - 60.64 %
Institutions - 19.31 %
Public - 19.73 %
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
